Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 8/20 | 0.48 |
| ▸ | LTA4H | P09960 | 4/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4522472 | 0.89 | FFAR1 (0.47) | PPARGKMT2AMEN1MAPTFFAR1 | |
| SCHEMBL4510798 | 0.86 | CYSLTR2 (0.53) | POLBCASP6TDP1L3MBTL1PPARG | |
| SCHEMBL14131791 | 0.84 | POLB (0.47) | POLBCASP6TDP1L3MBTL1PPARG | |
| SCHEMBL5118136 | 0.83 | POLB (0.46) | POLBCASP6TDP1L3MBTL1PPARG | |
| SCHEMBL8322921 | 0.82 | CYP1A2 (0.48) | TDP1L3MBTL1 | |
| SCHEMBL5119091 | 0.80 | MAPT (0.43) | POLBCASP6TDP1L3MBTL1PPARG | |
| SCHEMBL4373451 | 0.79 | KMT2A (0.61) | TDP1L3MBTL1PPARGKMT2AMEN1 | |
| SCHEMBL21828917 | 0.78 | CA12 (0.51) | POLBMAPT | |
| SCHEMBL4518834 | 0.78 | CYSLTR2 (0.46) | POLBCASP6TDP1L3MBTL1PPARG | |
| SCHEMBL5126470 | 0.77 | KMT2A (0.48) | POLBLTA4HCYSLTR2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | POLB 2956/4885CASP6 858/4885TDP1 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.